Experimental drug 'cures' hepatitis C in small trials
WASHINGTON (AFP) - An experimental drug combination cured 70 per cent of patients with hepatitis C in early trials, offering hope of a simpler remedy for the chronic liver disease, US researchers said on Tuesday.
The phase II trial described in the Journal of the American Medical Association (JAMA) studied the effectiveness and safety of an experimental drug, sofosbuvir, taken with the licensed antiviral drug ribavirin.
The drugs were administered orally, an improvement over the current treatment which involves weekly injections with interferon-alpha and can cause depression, flu-like symptoms and anemia.
Ten patients with early to moderate liver disease were treated with 400 milligrams daily of sofosbuvir and weight-based doses of ribavirin for six months.